Promising Triple-Drug cocktail targets untreated lymphoma
NCT ID NCT06522386
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 26 times
Summary
This study tests a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—in people with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see how many patients achieve a complete response (no cancer detected) after treatment. About 50 adults will take part, and researchers will also monitor side effects closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55902, United States
Conditions
Explore the condition pages connected to this study.